Bloom D, Krishnan B, Thavundayil J X, Lal S
Douglas Hospital Research Centre, Verdun, Quebec, Canada.
Acta Psychiatr Scand. 1993 Mar;87(3):223-4. doi: 10.1111/j.1600-0447.1993.tb03360.x.
Eleven chronic schizophrenic patients with abnormal skin pigmentation associated with neuroleptic treatment were withdrawn from chlorpromazine (CPZ), which was replaced by levomepromazine (n = 4), trifluoperazine (n = 1) or thioproperazine (n = 1) as the sole neuroleptic, by a combination of these phenothiazines (n = 4) or with haloperidol plus pipotiazine (n = 1). Seven patients showed complete resolution of abnormal skin pigmentation over a period of 1-5 years and 4 markedly improved over 2.0-2.6 years of follow-up. Our observations suggest that neuroleptic-induced abnormal skin pigmentation is (i) predominantly, if not exclusively, a side effect of CPZ and (ii) reversible, providing that CPZ is withdrawn and sufficient time is allowed to elapse.
11例接受抗精神病药物治疗后出现皮肤色素沉着异常的慢性精神分裂症患者停用了氯丙嗪(CPZ),分别换用左美丙嗪(4例)、三氟拉嗪(1例)或硫丙嗪(1例)作为单一抗精神病药物,或换用这些吩噻嗪类药物的联合制剂(4例),或换用氟哌啶醇加哌泊噻嗪(1例)。7例患者在1至5年的时间里皮肤色素沉着异常完全消退,4例在2.0至2.6年的随访中明显改善。我们的观察结果表明,抗精神病药物引起的皮肤色素沉着异常(i)如果不是完全由氯丙嗪引起,也是主要由其引起的副作用,(ii)如果停用氯丙嗪并给予足够的时间,是可逆的。